alexa Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment.
Oncology

Oncology

Journal of Nuclear Medicine & Radiation Therapy

Author(s): Richter JA, Rodrguez M, Rioja J, Peuelas I, MartCliment J,

Abstract Share this page

Abstract PURPOSE: The purpose of this study was to evaluate a dual tracer 2-deoxy-2-[F-18]fluoro-D: -glucose (FDG) and (11)C-choline positron emission tomography (PET) protocol in the detection of biochemical prostate cancer relapse. PROCEDURES: Seventy-three patients (median Prostate Specific Antigen (PSA) Test value 2.7 ng/ml (1.1-5.4)) after radical treatment. PET scans were performed by means of a ECAT-Exact HR+ in the first 18 patients and in a PET/computed tomography Biograph II in the remaining 55 patients. RESULTS: The sensitivity of (11)C-choline and FDG was 60.6\% and 31\%. In PSA levels over 1.9 ng/ml, sensitivity increased to 80\% and 40\%, respectively. In the group receiving adjuvant hormone therapy, the diagnostic yields were 71.2\% and 43\%, respectively. While (11)C-choline-PET could not differentiate well and poorly differentiated Gleason score patients, FDG-PET results were almost significant (p = 0.058). CONCLUSIONS: A PSA value higher than 1.9 ng/ml determines a significant increase in the diagnostic yield. Adjuvant hormonotherapy has no influence on the PET results. FDG has a better correlation with the Gleason score than (11)C-choline. This article was published in Mol Imaging Biol and referenced in Journal of Nuclear Medicine & Radiation Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords